Innate Pharma S.A. ADS (IPHA) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Innate Pharma S.A. ADS (IPHA) is Moderate Underperform.

The composite score behind that read is -0.27, weighing +0.05 of bullish evidence against -0.35 bearish.

Innate Pharma S.A. ADS last closed at $1.58, +1.28% on the session.

Against the IVW growth benchmark the position is +0.36% over the forecast window.

The read is built from 11 underlying insights — 3 bullish and 8 bearish.

Agreement across those insights is 73%.

16 graded predictions for IPHA so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

Innate Pharma S.A. ADS is classified under Health Care / Biotechnology, with a market capitalisation of $174.25M.

StockMap tracks Innate Pharma S.A. ADS as the 232nd largest of the 344 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 180 Moderate Underperform, 152 Neutral, 11 Strong Underperform and 1 Moderate Outperform.

On that composite Innate Pharma S.A. ADS ranks 232nd of 344 in the group, against a group median of -0.21.